Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.53 |
| ▸ | TST | Q16762 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10761871 | 0.86 | ESR1 (0.64) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28477538 | 0.86 | ESR1 (0.57) | ESR1ESR2SLC6A2SLC6A3LMNA | |
| SCHEMBL9412151 | 0.86 | ESR1 (0.57) | ESR1ESR2SLC6A2SLC6A3LMNA | |
| SCHEMBL980192 | 0.82 | SLC6A2 (0.59) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9616718 | 0.81 | ESR1 (0.62) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6686936 | 0.81 | ESR1 (0.52) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28732505 | 0.81 | ESR1 (0.62) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL237709 | 0.81 | ESR1 (0.62) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL573990 | 0.81 | ESR1 (0.62) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9225478 | 0.81 | ESR1 (0.57) | ESR1ESR2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841059-B2 | Crosslinking agent, negative resist composition, and pattern forming method using the negative resist composition | DAI NIPPON PRINTING CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8193274-B2 | Metal-clad laminates having improved peel strength and compositions useful for the preparation thereof | ARLON (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120115084-A1 | CROSSLINKING AGENT, NEGATIVE RESIST COMPOSITION, AND PATTERN FORMING METHOD USING THE NEGATIVE RESIST COMPOSITION | DAI NIPPON PRINTING CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20090176918-A1 | METAL-CLAD LAMINATES HAVING IMPROVED PEEL STRENGTH AND COMPOSITIONS USEFUL FOR THE PREPARATION THEREOF | ARLON | 2009-07-09 | — | — | US | disclosed |
| US-20090176106-A1 | METAL-CLAD LAMINATES HAVING IMPROVED PEEL STRENGTH AND COMPOSITIONS USEFUL FOR THE PREPARATION THEREOF | ARLON | 2009-07-09 | — | — | US | disclosed |
| US-7183323-B2 | Diaromatic compound containing 2-amine groups, useful for treating neuropathic pain | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040204460-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-10-14 | — | — | US | disclosed |
| US-6756400-B2 | Sodium channel modulators | THERAVANCE, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030027822-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-02-06 | — | — | US | disclosed |
| WO-2002018334-A2 | SODIUM CHANNEL MODULATORS | THERAVANCE, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115084-A1 | CROSSLINKING AGENT, NEGATIVE RESIST COMPOSITION, AND PATTERN FORMING METHOD USING THE NEGATIVE RESIST COMPOSITION | SEM1, ELL, POLL | ESR1 267/4885ESR2 61/4885SLC6A2 4689/4885 |
| US-20040204460-A1 | Sodium channel modulators | SCN1A, SCN1B, CACNA1A | ESR1 4336/4885ESR2 3460/4885SLC6A2 145/4885 |
| US-20030027822-A1 | Sodium channel modulators | SCN1A, SCN1B, CACNA1A | ESR1 4336/4885ESR2 3460/4885SLC6A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.